Completion of Retail Offer
York, U.K. 29 August 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), is pleased to announce that, further to the Company’s announcement dated 19 August 2024, , following the closing of the Retail Offer on the BookBuild Platform on 28 August 2024, 4,107,668 Ordinary Shares will be issued at a price of 9.75 pence per Retail Offer Share.
Consequently, 53,589,741 Placing Shares and 4,107,668 Retail Offer Shares, resulting in a total of 57,697,409 new Ordinary Shares, have been issued (or in the case of the Retail Offer Shares will be issued) in relation to the Placing and Retail Offer, raising total gross proceeds of £5.665 million.
Application has been made for the Retail Offer Shares to be admitted to trading on AIM (“Admission”). Admission is expected to take place at 8.00 a.m. on 30 August 2024.
Following the Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 193,630,821 with each Ordinary Share carrying the right to one vote. There are no Ordinary Shares held in treasury and therefore the total number of voting rights in the Company will be 193,630,821. The above figure may be used by Shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure, Guidance and Transparency Rules.
Capitalised terms used in this announcement have the meaning given to them in the Company’s placing and retail offer announcements dated 24 July 2024 and 19 August 2024, respectively, unless otherwise defined in this announcement.
Further information on the Company can be found on its website at: https://www.abingdonhealth.com/
This announcement should be read in its entirety. In particular, the information in the “Important Notices” section of the announcement should be read and understood.
Chris Yates, CEO, commented: “We are delighted to complete this offer to retail shareholders in addition to the Placing announced on 19 August 2024, both of which were done at a minor discount to the market price. The Company is now well placed to continue its growth with the combined strength of Abingdon Health, CS (Life Sciences) Group and IVDeology giving a full service offering to our CRO and CDMO clients. In addition, the investments allow us to add additional Analytical Laboratory services and capacity and provides the Company with additional product development resources. We appreciate the continued support of our current and new shareholders, and I look forward to updating on progress in due course”
For further information, please contact:
|
|
||||||||||||
|
||||||||||||
